Invivyd, Inc. They utilize cutting-edge technology that combines evolutionary virology, predictive modeling, and antibody engineering to identify top-quality, long-lasting antibodies with a high resistance to viral escape. Invivyd is actively developing a strong pipeline of product candidates that can be utilized for the prevention and treatment of major viral illnesses, beginning with COVID-19 and expanding to include influenza and other critical indications.

The company acknowledges the weakness and short duration of mucosal immunity in respiratory infections and aims to bridge the gap by creating engineered antibodies that surpass naturally occurring ones. Their platform approach has resulted in a pipeline of advanced antibodies that provide robust and broad neutralization against known SARS-CoV-2 variants, including Omicron sub-lineages. Beyond COVID-19, Invivyd is leveraging its robust discovery and development capabilities to explore therapeutic and preventative options for respiratory viral infections such as seasonal influenza